Summary of study ST001515

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001022. The data can be accessed directly via it's Project DOI: 10.21228/M8KT26 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Download all metabolite data  |  Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST001515
Study TitleA Metabolomic Signature of Glucagon Action in Healthy Individuals with Overweight/Obesity Humans
Study SummaryObjective: We sought to identify the circulating metabolites that would serve as markers of glucagon action. Design: In this study, we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity. Participants were randomized to either glucagon (12.5 ng/kg/min) (GCG 12.5) or glucagon (25 ng/kg/min) GCG 25 or a placebo control were included. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity.
Institute
Translational Research Institute- AdventHealth Orlando
Last NameWhytock
First NameKatie
Address301 E Princeton St, Orlando, FL, 32804
EmailKatie.Whytock@adventhealth.com
Phone321-945-9982
Submit Date2020-10-26
Num Groups3
Total Subjects33
Raw Data AvailableYes
Raw Data File Type(s)excel
Analysis Type DetailOther
Release Date2020-12-01
Release Version1
Katie Whytock Katie Whytock
https://dx.doi.org/10.21228/M8KT26
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001022
Project DOI:doi: 10.21228/M8KT26
Project Title:Effects of glucagon infusion on plasma metabolome in individuals with overweight/obesity
Project Summary:Objective: We sought to identify the circulating metabolites that would serve as markers of glucagon action. Design: In this study, we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity. Participants were randomized to either glucagon (12.5 ng/kg/min) (GCG 12.5) or glucagon (25 ng/kg/min) GCG 25 or a placebo control were included. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity.
Institute:Translational Research Institute- AdventHealth Orlando
Last Name:Whytock
First Name:Katie
Address:301 E Princeton St, FL, USA, 32804
Email:Katie.Whytock@adventhealth.com
Phone:3219459982
Funding Source:Sanofi
  logo